Document:

EX-10.8

 Exhibit 10.8 

RESTRICTED STOCK GRANT AGREEMENT 

THIS AGREEMENT is made as of the 30th day of December, 2018, by and between IGM
Biosciences, Inc., a Delaware corporation (the “Company”), and Daniel S. Chen, MD, PhD (the “Grantee”). 
 In
consideration of the mutual covenants and representations herein set forth, the Company and the Grantee agree as follows: 

1.    Grant of Stock. Subject to the terms and conditions of this Agreement, the Company hereby grants to
the Grantee 770,000 shares of the Company’s Common Stock (the “Stock”) having a fair market value as of the date of this Agreement of $0.21 per share. This grant is made pursuant to the Employment Agreement dated as of July 12,
2018 between the Company and the Grantee (the “Employment Agreement”) and is in full satisfaction of the Company’s obligation under Section 3(b) thereof. This grant is not made pursuant to the Company’s 2018 Omnibus
Incentive Plan or its 2010 Stock Plan. The Stock will be registered in the name of Grantee as of the date of this Agreement in book-entry form and will be held by the Company in escrow until the forfeiture provisions under Section 2 have
lapsed. Evidence of book-entry shares of Stock with respect to which the forfeiture provisions in Section 2 have lapsed shall be delivered to the Grantee as soon as practicable following the date on which the restrictions on such shares have
lapsed. 
 2.    Forfeiture. If Grantee voluntarily terminates his employment for any reason other than
Good Reason (as defined in the Employment Agreement) or if the Company terminates his employment for Cause (as defined in the Employment Agreement) on or before August 1, 2019, all of the Stock will be automatically forfeited by Executive
without consideration. If Executive voluntarily terminates his employment for any reason other than Good Reason or if the Company terminates his employment for Cause after August 1, 2019 but on or before August 1, 2020, 385,000 shares of
the Stock will be automatically forfeited by Grantee without consideration. If any certificates representing shares of Stock have been delivered to Grantee, upon a forfeiture the Grantee shall within ten (10) business days thereafter, deliver
to the Company any and all stock certificates representing all shares of the forfeited Stock, together with stock powers duly executed in blank by the Grantee. From and after the occurrence of such forfeiture, and notwithstanding any provision
herein to the contrary, the Grantee shall have no rights to or interests in any shares of the forfeited Stock (other than the obligation to transfer and deliver any and all stock certificates representing all shares of forfeited Stock pursuant to
this Section 2). 
 3.    Restriction on Transfer; Rights of First Refusal. Shares of Stock which are
subject to the forfeiture provisions of Section 2 hereof shall not be transferable by Grantee. Any sale, pledge or other transfer of shares of Stock that are no longer subject to the forfeiture provisions under Section 2 hereof shall be
subject to the right of first refusal (the “Right of First Refusal”) set forth in the Bylaws of the Company. 

4.    Voting and Dividend Rights. Grantee, as beneficial owner of the Stock, shall have full voting rights
with respect to the shares of Stock whether before and after the forfeiture provisions of Section 2 hereof have lapsed. Grantee shall accrue cash and non-cash

 
dividends, if any, paid with respect to shares subject to the forfeiture provisions of Section 2, but the payment of such dividends shall be deferred and held (without interest) by the
Company for the account of Grantee until the forfeiture provisions of Section 2 hereof have lapsed with respect to such shares. Until the forfeiture provisions of Section 2 hereof have lapsed with respect to such shares, such dividends
shall be subject to the same vesting restrictions imposed under Section 2 as the shares to which they relate. Accrued dividends deferred and held pursuant to the foregoing provision shall be paid by the Company to the Grantee within thirty
(30) days following the expiration of the applicable forfeiture provisions. 
 5.    Stock Splits,
etc. If, from time to time during the term of the forfeiture provisions or Right of First Refusal as provided in Sections 2 and 3 hereof, there is any stock dividend, stock split or other change in the character or amount of any of the
outstanding securities of the Company or if there is any consolidation, merger or sale of all, or substantially all, of the assets of the Company, then in such event any and all new, substituted or additional securities to which Grantee is entitled
by reason of its ownership of capital stock shall be immediately subject to the forfeiture provisions and Rights of First Refusal and be included in the term “Stock” for all purposes of this Agreement with the same force and effect as the
shares of Stock presently subject to this Agreement. 
 6.    Investment Intent; Covenant. In purchasing
the Stock, Grantee represents to the Company as follows: 
 (a)    Grantee has had an opportunity to discuss the
business prospects and business plan of the Company with the officers and directors of the Company. Grantee has a preexisting personal or business relationship with the Company or one of its officers, directors or controlling persons and/or by
reason of Grantee’s business or financial experience Grantee has the capacity to protect Grantee’s own interests in connection with the transactions contemplated by this Agreement. Grantee further acknowledges that the Stock is highly
speculative and involves a high degree of risk, and represents and warrants that Grantee is able, without impairing Grantee’s financial condition, to hold the Stock for an indefinite period of time and suffer a complete loss of Grantee’s
investment therein. 
 (b)    Grantee is acquiring the Stock for investment and not with a view to or for sale in
connection with any distribution of said Stock or with any present intention of distributing or selling said Stock and Grantee does not presently have reason to anticipate any change in circumstances or any particular occasion or event which would
cause Grantee to sell said Stock. Grantee understands that the Stock has not been registered under the Securities Act of 1933, as amended, (the “Act”) and may not be sold or otherwise disposed of except pursuant to an effective
Registration Statement filed under the Act or pursuant to an exemption from the registration requirements of such Act. Grantee acknowledges that the Company is under no obligation to register the Stock under the Act on Grantee’s behalf. Grantee
represents and warrants that Grantee understands that the Stock constitutes restricted securities within the meaning of Rule 144 promulgated under the Act; that the exemption from registration under Rule 144 will not be available in any event for at
least one year from the date of purchase and payment for the Stock, and even then will not be available unless the terms and conditions of Rule 144 are complied with and will be subject to the limitations on amount set forth therein. 

  
 2 

 (c) Without limiting the representations and warranties set forth above, Grantee agrees
Grantee will not make any transfer of all or any part of the Stock unless (i) there is a Registration Statement under the Act in effect with respect to such transfer and such transfer is made in accordance therewith, or (ii) Grantee has
furnished the Company a written opinion of counsel satisfactory to the Company and its counsel to the effect that such transfer will not require registration under the Act, which requirement the Company may waive in its discretion. Grantee agrees
that, prior to the closing of the Company’s initial public offering registered under the Act, Grantee will not transfer any of such securities in a public offering without the Company’s prior consent, even if Grantee is otherwise permitted
to transfer them pursuant to Rule 144 under the Act. 
 (d)    Grantee is an accredited investor as defined in Rule
501(a) of Regulation D promulgated under the Act. 
 7.    Market
Stand-Off Agreement. In the event the Company sells any of its securities in an underwritten initial public offering pursuant to a registration filed pursuant to the Act, including the Company’s
initial public offering, Grantee shall not sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of, any of capital stock of the Company, or otherwise agree to engage in any of the foregoing transactions,
without the prior written consent of the Company or such underwriters, for such period of time from and after the effective date of such registration statement as may be requested by the Company or such underwriters; provided, however, that
such period shall not exceed one hundred eighty (180) days; and provided, further, that such 180-day period may be extended for not more than eighteen (18) days if such extension is
reasonably necessary to allow the Company’s underwriters to comply with FINRA Rule 2711 (or any similar successor rule). In order to enforce the provisions of this Section, the Company may impose stop-transfer instructions with respect to the
Shares until the end of the applicable stand-off period. 
 8.    Payment
of Taxes. Upon issuance of the Stock hereunder, Grantee may make an election to be taxed upon such award under Section 83(b) of the Code (an “83(b) Election”). To effect such 83(b) Election, Grantee may file an appropriate
election with Internal Revenue Service within 30 days after award of the Stock and otherwise in accordance with applicable Treasury Regulations. The Company has the authority and the right to deduct or withhold, or require Grantee to remit to the
Company, an amount sufficient to satisfy federal, state, and local taxes (including Grantee’s FICA obligation) required by law to be withheld with respect to any taxable event arising as a result of the grant or vesting of the Stock. At the
election of the Company, the withholding requirement may be satisfied, in whole or in part, by withholding, from the Stock, shares having a fair market value on the date of withholding equal to the amount required to be withheld for tax purposes
under applicable law. The obligations of the Company under this Agreement will be conditional on such payment or arrangements, and the Company will, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind
otherwise due to Grantee. 
 9.    Miscellaneous. 

9.1    Further Assurances. Grantee agrees to execute such further documents and to take such further action
as the Company in its judgment may deem necessary or advisable to carry out or effect one or more obligations or restrictions imposed on either Grantee or the Stock pursuant to the express provisions of this Agreement. 

  
 3 

 9.2    Entire Agreement; Amendment; Counterparts. This
Agreement, including any exhibits, is the entire agreement of the parties with respect to the subject matter hereof and supersedes all prior oral and written understandings of the parties. This Agreement may not be changed or amended except by a
writing, stating that it is an amendment to this Agreement, executed by both parties hereto. This Agreement may be signed in one or more counterparts, each of which will be considered an original, but all of which together form one and the same
instrument. 
 9.3    Notices. Any notice required or permitted hereunder shall be given in writing and
shall be deemed effectively given upon personal delivery or upon deposit in the United States Post Office, by registered or certified mail with postage and fees prepaid, addressed to Grantee at his or her address shown on the Company’s
employment or other records and to the Company at the address of its principal corporate offices (attention: Chief Executive Officer) or at such other address as such party may designate by ten (10) days’ advance written notice to the
other party hereto. 
 9.4    Assignment of Rights; Binding Upon Successors. This Agreement shall inure to
the benefit of the successors and assigns of the Company and, subject to the restrictions on transfer herein set forth, be binding upon Grantee and Grantee’s heirs, executors, administrators, successors and assigns. 

9.5    Interpretation. In construing or interpreting this Agreement (and the Exhibits), the word
“or” shall mean either or both (unless the context clearly requires otherwise), and the word “include” or “including” shall not be limiting or exclusive. This Agreement shall be interpreted fairly in accordance with its
terms and without strict construction in favor or against either party and ambiguities shall not be interpreted against the drafting party. 

9.6    Waiver; Severability. No delay or failure by either party to exercise or enforce at any time
any right or provision of this Agreement shall be considered a waiver thereof or of such party’s right thereafter to exercise or enforce each and every right and provision of this Agreement. If any provision of this Agreement is determined to
be illegal, invalid or unenforceable, it shall be modified to render it legal, valid and enforceable while to the fullest extent possible preserving the business and financial intent and impact of the original provision, and if such modification is
not feasible such provision shall be severed and the legality, validity and enforceability of all other provisions of this Agreement shall not be affected thereby. 

9.7    Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the
State of California as applied to contracts between California residents to be wholly performed within the State of California. 

[remainder of page intentionally blank] 

  
 4 

 9.8    Counterparts: Facsimile Signatures. This Agreement
may be executed in two or more counterparts, each of which will be deemed an original, and all of which, collectively, will constitute only one agreement. This Agreement is effective upon delivery of one executed counterpart from each party to the
other party or parties, including by facsimile or other electronic form. 
 IN WITNESS WHEREOF, the parties hereto have executed this
Agreement as of the day and year first above written. 
  

			
	IGM BIOSCIENCES, INC.
	a Delaware corporation
		
	By:	 	 /s/ Fred Schwarzer

	Name:	 	Fred M. Schwarzer
	Title:	 	Chief Executive Officer
	
	GRANTEE
	
	 /s/ Daniel S. Chen

	DANIEL S. CHEN, MD, PhD

  
 5 

 CONSENT OF SPOUSE 

I, [***], spouse of Daniel S. Chen, have read and approved the foregoing Restricted Stock Grant Agreement and the exhibits thereto (the
“Agreement”). In consideration of the Company’s granting my spouse the right to purchase the Stock as set forth in the Agreement, I hereby agree to be irrevocably bound by the Agreement and further agree that any interest I might have
in such Stock shall be similarly bound by the Agreement. I hereby appoint my spouse as my attorney-in-fact with respect to any amendment or exercise of any rights under
the Agreement. 
  

			
	Dated: December 30, 2018	 	 /s/ [***]

		 	Spouse of GranteeEX-10.9

 Exhibit 10.9 
  

 
 August 19, 2019 

Mr. Bruce Keyt 
 c/o IGM Biosciences, Inc. 

325 E. Middlefield Road 
 Mountain View, CA 94043 

Dear Mr. Keyt: 
 This letter agreement (the
“Agreement”) is entered into between Bruce Keyt (“you”) and IGM Biosciences, Inc. (the “Company” or “we”), effective as of August 19, 2019 (the “Effective Date”), to
confirm the terms and conditions of your employment with the Company as of the Effective Date. This Agreement supersedes and replaces any and all employment terms, compensation, or benefits you may have had or to which you may have been entitled
prior to the Effective Date. 
 1. Title/Position. You will continue to serve as the Company’s Chief Scientific Officer.
You also will continue to report to the Company’s Chief Executive Officer and will perform the duties and responsibilities customary for such position and such other related duties as are lawfully assigned by the Company’s Chief Executive
Officer. By signing this Agreement, you confirm that you continue to have no contractual commitments or other legal obligations that would prohibit you from performing your duties for the Company. 

2. Base Salary. As of the Effective Date, your annual base salary is $357,000, which will be payable, less any applicable
withholdings, in accordance with the Company’s normal payroll practices. Your annual base salary will be subject to review and adjustment from time to time by our Board or its Compensation Committee (the “Committee”), as
applicable, in its sole discretion. 
 3. Annual Bonus. For the Company’s 2019 fiscal year, you will have the opportunity
to earn a target annual cash bonus equal to 35% of your annual base salary earned during the fiscal year, based on achieving performance objectives established by the Board or Committee, as applicable, in its sole discretion and payable upon
achievement of those objectives as determined by the Committee. Unless determined otherwise by the Board or Committee, as applicable, any such bonus will be subject to your continued employment through and until the date of payment. Your annual
bonus opportunity and the applicable terms and conditions may be adjusted from time to time by our Board or the Committee, as applicable, in its sole discretion. 

4. Equity Awards. You will be eligible to receive awards of stock options, restricted stock units or other equity awards
pursuant to any plans or arrangements the Company may have in effect from time to time. The Board or Committee, as applicable, will determine in its sole discretion whether you will be granted any such equity awards and the terms of any such award
in accordance with the terms of any applicable plan or arrangement that may be in effect from time to time. Your equity awards outstanding as of the Effective Date will continue in effect on their existing terms. 

  
 325 E. Middlefield Road
Mountain View, CA 94043 Tel: 650-965-7873 

 5. Employee Benefits. You will continue to be eligible to participate in the
benefit plans and programs established by the Company for its employees from time to time, subject to their applicable terms and conditions, including without limitation any eligibility requirements. The Company reserves the right to modify, amend,
suspend or terminate the benefit plans and programs it offers to its employees at any time. 
 6. Severance. As of the
Effective Date, you will be eligible to participate in the Company’s Change in Control and Severance Policy (the “CIC/Severance Policy”) with the benefits applicable to you based on your position within the Company. The
CIC/Severance Policy and the participation agreement under the CIC/Severance Policy that you signed at the same time as this letter specify the severance payments and benefits you may become entitled to receive in connection with certain qualifying
terminations of your employment with the Company. These protections supersede all other severance payments and benefits to which you otherwise may be entitled, or may become entitled in the future, under any plan, program or policy that the Company
may have in effect from time to time. For purposes of clarification, any severance benefits or arrangements that may have applied to you before the Effective Date no longer will apply and you will have no rights or entitlements under any such plans,
programs, agreements or arrangements. 
 7. Confidentiality Agreement. As an employee of the Company, you will continue to
have access to certain confidential information of the Company and you may, during the course of your employment, develop certain information or inventions that will be the property of the Company. To protect the interests of the Company, your
acceptance of this Agreement confirms that the terms of the Employee Proprietary Information and Inventions Agreement you previously signed with the Company (the “Confidentiality Agreement”) still apply. 

8. At-Will Employment. This Agreement does not imply any right to your continued
employment for any period with the Company or any of its affiliates. Your employment with the Company will continue to be “at will.” It is for no specified term, and may be terminated by you or the Company at any time, with or without
cause or advance notice. 
 9. Protected Activity Not Prohibited. Nothing in this Agreement or in any other agreement between
you and the Company, as applicable, will in any way limit or prohibit you from engaging for a lawful purpose in any Protected Activity. For purposes of this Agreement, “Protected Activity” means filing a charge, complaint, or report
with, or otherwise communicating, cooperating, or participating in any investigation or proceeding that may be conducted by, any state, federal, or local governmental agency or commission, including the U.S. Securities and Exchange Commission, the
Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and the National Labor Relations Board (the “Government Agencies”). You understand that in connection with such Protected Activity, you are
permitted to disclose documents or other information as permitted by law, and without giving notice to, or receiving authorization from, the Company. Notwithstanding the foregoing, you agree to take all reasonable precautions to prevent any
unauthorized use or disclosure of any information that may constitute Company confidential information under the Confidentiality Agreement to any parties other than the Government Agencies. You further understand that “Protected Activity”
does not include the disclosure of any Company attorney-client privileged communications. Any language in the Confidentiality Agreement regarding your right to engage in Protected Activity that conflicts with, or is

  
 2 

 
contrary to, this paragraph is superseded by this Agreement. In addition, pursuant to the Defend Trade Secrets Act of 2016, you are notified that an individual will not be held criminally or
civilly liable under any federal or state trade secret law for the disclosure of a trade secret that (i) is made in confidence to a federal, state, or local government official (directly or indirectly) or to an attorney solely for the purpose
of reporting or investigating a suspected violation of law, or (ii) is made in a complaint or other document filed in a lawsuit or other proceeding, if (and only if) such filing is made under seal. In addition, an individual who files a lawsuit
for retaliation by an employer for reporting a suspected violation of law may disclose the trade secret to the individual’s attorney and use the trade secret information in the court proceeding, if the individual files any document containing
the trade secret under seal and does not disclose the trade secret, except pursuant to court order. 
 10. Miscellaneous. This
Agreement, together with the Confidentiality Agreement, the CIC/Severance Policy and any outstanding equity awards granted to you by the Company under its 2010 Stock Plan and 2018 Omnibus Incentive Plan and the applicable award agreements
thereunder, constitute the entire agreement between you and the Company regarding the material terms and conditions of your employment, and they supersede and replace all prior negotiations, representations or agreements between you and the Company.
This Agreement may be modified only by a written agreement signed by you and a duly authorized officer of the Company. 
 [Signature page
follows.] 

  
 3 

 To confirm the current terms and conditions of your employment, please sign and date in the spaces indicated
and return this Agreement to me. 
  

	
	Sincerely,
	
	IGM Biosciences, Inc.
	
	/s/ Suzette Tauber
	
	Suzette Tauber
	
	Vice President, Human Resources
	
	ACCEPTED AND AGREED TO this
	
	19 day of August, 2019.
	
	/s/ Bruce Keyt
	Bruce Keyt

  
 4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00299-of-00352.parquet"}]]